[Prophylactic gastrectomy].

Perrine Côme, Pauline Rochefort, Lucas De Crignis, Aurélien Dupré
{"title":"[Prophylactic gastrectomy].","authors":"Perrine Côme, Pauline Rochefort, Lucas De Crignis, Aurélien Dupré","doi":"10.1016/j.bulcan.2024.04.003","DOIUrl":null,"url":null,"abstract":"<p><p>One to 3% of gastric cancers are secondary to genetic predisposition, notably hereditary diffuse gastric cancers (HDGC) caused by CDH1 gene mutations. According to French recommendations, in case of CDH1 gene mutation, a prophylactic total gastrectomy should be performed between 20 and 30 years old. This gastrectomy should remove all the gastric mucosa at both extremities (duodenal and esophageal sides). Histopathological examinations of prophylactic total gastrectomies in asymptomatic CDH1-mutated patients reveal microscopic foci of diffuse-type cancer in 90 to 100% of cases. Lymph node involvement and lympho-vascular invasion are extremely rare, justifying the use of a D1-only lymphadenectomy. In the context of prophylaxis, limited lymphadenectomy and the development of minimally invasive oesogastric surgery, the minimally invasive approach might be the preferred approach, in expert centers. Surgical outcomes seem to be similar to those after gastrectomy for cancer. Prophylactic total gastrectomy is the cornerstone of CGDH management, associated with multidisciplinary follow-up and mammary surveillance in women.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2024.04.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

One to 3% of gastric cancers are secondary to genetic predisposition, notably hereditary diffuse gastric cancers (HDGC) caused by CDH1 gene mutations. According to French recommendations, in case of CDH1 gene mutation, a prophylactic total gastrectomy should be performed between 20 and 30 years old. This gastrectomy should remove all the gastric mucosa at both extremities (duodenal and esophageal sides). Histopathological examinations of prophylactic total gastrectomies in asymptomatic CDH1-mutated patients reveal microscopic foci of diffuse-type cancer in 90 to 100% of cases. Lymph node involvement and lympho-vascular invasion are extremely rare, justifying the use of a D1-only lymphadenectomy. In the context of prophylaxis, limited lymphadenectomy and the development of minimally invasive oesogastric surgery, the minimally invasive approach might be the preferred approach, in expert centers. Surgical outcomes seem to be similar to those after gastrectomy for cancer. Prophylactic total gastrectomy is the cornerstone of CGDH management, associated with multidisciplinary follow-up and mammary surveillance in women.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[预防性胃切除术]。
1%至3%的胃癌是继发于遗传易感性,尤其是由CDH1基因突变引起的遗传性弥漫性胃癌(HDGC)。根据法国的建议,如果 CDH1 基因突变,应在 20 至 30 岁之间进行预防性全胃切除术。胃切除术应切除两端(十二指肠侧和食管侧)的所有胃黏膜。对无症状的 CDH1 基因突变患者进行的预防性全胃切除术的组织病理学检查显示,90% 至 100%的病例存在弥漫型癌症的显微病灶。淋巴结受累和淋巴管侵犯的情况极为罕见,因此有理由采用仅D1淋巴结切除术。在预防、有限淋巴结切除和微创肛胃手术发展的背景下,微创方法可能是专家中心的首选方法。手术结果似乎与癌症胃切除术后的结果相似。预防性全胃切除术是 CGDH 治疗的基石,与多学科随访和女性乳腺监测相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Nivolumab plus chemotherapy in neoadjuvant treatment of NSCLC with PD-L1 expression≥1]. [Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy]. [Molecular profiling in biliary tract cancers: A national practice survey of French platforms]. [Perioperative pembrolizumab for early-stage non-small-cell lung cancer]. [Development and validation of a tool for the systematic identification of social vulnerabilities in cancer patients: the DEFCO tool].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1